Unity Biotechnology, Inc. (UBX)
NASDAQ: UBX · Real-Time Price · USD
1.152
-0.018 (-1.54%)
Nov 21, 2024, 11:50 AM EST - Market open
Unity Biotechnology Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Revenue | - | - | 0.24 | 4.78 | - | - | Upgrade
|
| Revenue Growth (YoY) | - | - | -95.07% | - | - | - | Upgrade
|
| Cost of Revenue | 18.39 | 19.7 | 35.46 | 38.39 | 67.31 | 70.96 | Upgrade
|
| Gross Profit | -18.39 | -19.7 | -35.22 | -33.61 | -67.31 | -70.96 | Upgrade
|
| Selling, General & Admin | 15.42 | 18.77 | 20.45 | 23.06 | 24.03 | 20.05 | Upgrade
|
| Research & Development | -5.55 | - | - | - | - | - | Upgrade
|
| Operating Expenses | 9.87 | 18.77 | 20.45 | 23.06 | 24.03 | 20.05 | Upgrade
|
| Operating Income | -28.26 | -38.47 | -55.67 | -56.67 | -91.33 | -91 | Upgrade
|
| Interest Expense | -0 | -2.45 | -3.56 | -3.18 | -1.29 | - | Upgrade
|
| Interest & Investment Income | 1.95 | 2.87 | 1.22 | 0.1 | 1.2 | 3.29 | Upgrade
|
| Other Non Operating Income (Expenses) | 5.4 | 4.76 | 14.9 | -1.11 | -0.32 | -0.32 | Upgrade
|
| EBT Excluding Unusual Items | -20.91 | -33.28 | -43.11 | -60.85 | -91.75 | -88.04 | Upgrade
|
| Merger & Restructuring Charges | -0.6 | -0.6 | -1.9 | - | -2.63 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.5 | 4.51 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.11 | 0.11 | 0.35 | - | - | - | Upgrade
|
| Asset Writedown | - | -5.6 | - | - | - | - | Upgrade
|
| Other Unusual Items | -0.49 | -0.49 | 0.2 | 0.12 | 0.03 | 1.35 | Upgrade
|
| Pretax Income | -21.89 | -39.86 | -44.47 | -60.73 | -93.84 | -82.18 | Upgrade
|
| Earnings From Continuing Operations | - | -39.86 | -44.47 | -60.73 | -93.84 | -82.18 | Upgrade
|
| Net Income | -21.89 | -39.86 | -44.47 | -60.73 | -93.84 | -82.18 | Upgrade
|
| Net Income to Common | -21.89 | -39.86 | -44.47 | -60.73 | -93.84 | -82.18 | Upgrade
|
| Shares Outstanding (Basic) | 17 | 15 | 9 | 6 | 5 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 17 | 15 | 9 | 6 | 5 | 4 | Upgrade
|
| Shares Change (YoY) | 15.08% | 55.60% | 70.10% | 9.73% | 16.60% | 54.32% | Upgrade
|
| EPS (Basic) | -1.32 | -2.70 | -4.68 | -10.88 | -18.45 | -18.84 | Upgrade
|
| EPS (Diluted) | -1.32 | -2.70 | -4.68 | -10.88 | -18.45 | -18.84 | Upgrade
|
| Free Cash Flow | -22.54 | -37.1 | -52.51 | -45.26 | -78.98 | -74.01 | Upgrade
|
| Free Cash Flow Per Share | -1.36 | -2.51 | -5.53 | -8.11 | -15.53 | -16.96 | Upgrade
|
| Operating Margin | - | - | -23589.83% | -1184.47% | - | - | Upgrade
|
| Profit Margin | - | - | -18842.80% | -1269.34% | - | - | Upgrade
|
| Free Cash Flow Margin | - | - | -22250.00% | -945.97% | - | - | Upgrade
|
| EBITDA | -27.36 | -37.28 | -53.49 | -53.79 | -87.89 | -89.62 | Upgrade
|
| D&A For EBITDA | 0.9 | 1.18 | 2.18 | 2.88 | 3.45 | 1.39 | Upgrade
|
| EBIT | -28.26 | -38.47 | -55.67 | -56.67 | -91.33 | -91 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.